Fatigue is a core symptom of chronic liver disease (CLD) and is known to impair daily functioning and health‑related quality of life (HRQoL). The a:GAP (Abbott Global Assessment of Patients unmet needs) study aimed to describe symptom burden, with emphasis on fatigue, and its impact on HRQoL from the patient perspective in adults with compensated CLD across multiple countries.
The a:GAP study was a multinational, cross-sectional survey conducted between July and November 2024 in China, India and Mexico. The analysis included 505 adults who self-reported physician-diagnosed compensated CLD and current fatigue. Country enrollment was China (n=200), India (n=200) and Mexico (n=105). Participants completed a quantitative survey about symptom burden and HRQoL.
The study incorporated three validated patient-reported outcome (PRO) instruments alongside symptom questions:
These PROs were used to quantify the severity and functional consequences of fatigue and related symptoms.
Participants frequently reported substantial, persistent fatigue. Overall, 51.3% described their fatigue as moderate and 26.9% as serious. One third (33.5%) experienced fatigue every day or almost every day. Beyond symptom severity, fatigue had measurable impacts on psychosocial and socioeconomic domains: 45.1% reported that fatigue sometimes, often or always affected self-esteem or confidence; 38.6% felt it affected their ability to maintain or obtain employment. Nearly half (47.3%) reported a negative impact on social life, and a majority (53.9%) reported related financial difficulties.
The PRO instruments confirmed high fatigue severity and broad functional impairment. On the MFI, participants demonstrated severe fatigue with overall mean (SD) scores reported for general fatigue at 13.9 (3.4) and physical fatigue at 13.4 (3.6). The WPAI: SHP indicated substantial work and activity impairment with an overall mean (SD) of 53.0 (26.4), reflecting notable loss in productivity and daily activities attributable to CLD-related fatigue. PROMIS T-scores were elevated for several symptom domains — anxiety, pain interference, depression and sleep interference — with mean T-scores ≥54, indicating higher symptom burden compared with population norms.
Findings from the a:GAP survey demonstrate that fatigue in compensated CLD is common, often severe, and associated with significant deterioration in HRQoL, work productivity, social participation and financial status across diverse geographic settings. The combination of patient-reported symptom frequency, psychosocial impact, and elevated PRO scores underscores a substantial unmet need for improved recognition, evaluation, and targeted management strategies for fatigue in CLD. The authors highlight this as a global concern warranting further research and interventional development.
The study received approval from country-specific independent ethics committees (India: Royal Pune Independent Ethics Committee; China: Shanghai Clinical Research Ethics Committee; Mexico: CEISH-USFQ University of San Francisco Ethics Committee) and followed principles of the Declaration of Helsinki and relevant good practice guidelines. The work was funded by Abbott Products Operations AG. The report is a preprint and has not been peer reviewed; therefore findings should not yet be used to guide clinical practice. All data and supporting information are reported within the paper and supplementary files.
Several authors were employees of Abbott Products Operations AG or Oracle Health and Life Sciences at the time of the study. One author reported multiple advisory and speaker relationships and receipt of clinical trial funding from several industry organizations. These competing interests are declared in the source report.
The source text does not provide detailed methods beyond the high-level design (cross-sectional, self-reported physician diagnosis, country sample sizes) nor does it present subgroup analyses, response rates, recruitment strategies, or longitudinal follow-up. Those details were not reported in the abstract and should be consulted in the full manuscript or supplementary material for comprehensive appraisal.